- Home
- CMRX vs CERS Comparison
CMRX vs CERS Comparison
Compare CMRX & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- CERS
- Stock Information
- Founded
- CMRX 2000
- CERS 1991
- Country
- CMRX United States
- CERS United States
- Employees
- CMRX N/A
- CERS N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- CERS EDP Services
- Sector
- CMRX Health Care
- CERS Technology
- Exchange
- CMRX Nasdaq
- CERS Nasdaq
- Market Cap
- CMRX 394.1M
- CERS 347.3M
- IPO Year
- CMRX 2013
- CERS 1997
- Fundamental
- Price
- CMRX $5.15
- CERS $1.65
- Analyst Decision
- CMRX Strong Buy
- CERS Buy
- Analyst Count
- CMRX 2
- CERS 3
- Target Price
- CMRX $8.50
- CERS $3.17
- AVG Volume (30 Days)
- CMRX 1.7M
- CERS 1.6M
- Earning Date
- CMRX 03-07-2025
- CERS 02-20-2025
- Dividend Yield
- CMRX N/A
- CERS N/A
- EPS Growth
- CMRX N/A
- CERS N/A
- EPS
- CMRX N/A
- CERS N/A
- Revenue
- CMRX $159,000.00
- CERS $180,270,000.00
- Revenue This Year
- CMRX N/A
- CERS $15.95
- Revenue Next Year
- CMRX $1,690.28
- CERS $10.50
- P/E Ratio
- CMRX N/A
- CERS N/A
- Revenue Growth
- CMRX N/A
- CERS 15.29
- 52 Week Low
- CMRX $0.75
- CERS $1.38
- 52 Week High
- CMRX $5.53
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- CMRX 76.25
- CERS 41.40
- Support Level
- CMRX $3.94
- CERS $1.64
- Resistance Level
- CMRX $5.53
- CERS $1.96
- Average True Range (ATR)
- CMRX 0.30
- CERS 0.11
- MACD
- CMRX 0.07
- CERS -0.02
- Stochastic Oscillator
- CMRX 78.29
- CERS 3.12
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.